PMID- 32002845
OWN - NLM
STAT- MEDLINE
DCOM- 20220322
LR  - 20240130
IS  - 1532-6551 (Electronic)
IS  - 1071-3581 (Linking)
VI  - 28
IP  - 5
DP  - 2021 Oct
TI  - Myocardial viability with chronic total occlusion assessed by hybrid positron 
      emission tomography/magnetic resonance imaging.
PG  - 2335-2342
LID - 10.1007/s12350-020-02041-3 [doi]
AB  - BACKGROUND: The present study was performed to compare the relationship of 
      (18)F-fluorodeoxyglucose (FDG) uptake and late gadolinium enhancement (LGE) 
      transmurality with the improvement of left ventricular function in patients with 
      coronary chronic total occlusion (CTO) assessed by hybrid FDG positron emission 
      tomography (PET)/magnetic resonance imaging (MRI). METHODS: Thirty-eight 
      consecutive patients with CTO underwent FDG PET/MRI. Twenty-three patients then 
      underwent percutaneous coronary intervention (PCI), and the final study 
      population comprised 15 patients who underwent both initial and follow-up MRI. 
      The degree of wall motion abnormality in each of the 17 myocardial segments was 
      evaluated based on the extent of wall thickening on cine MRI using a 5-point 
      scale. RESULTS: Among all 646 myocardial segments at baseline, FDG uptake 
      significantly decreased as the transmurality of LGE is advanced. Of the 15 
      patients who underwent PCI, 152 segments showed wall motion abnormalities at 
      baseline. The functional recovery of the wall motion abnormality of the 
      PET-viable/MRI-viable segments was highest, and that of the 
      PET-nonviable/MRI-nonviable segments was lowest. There were no differences in 
      functional recovery between the PET-viable/MRI-nonviable and 
      PET-nonviable/MRI-viable segments. CONCLUSION: Simultaneous assessment of FDG and 
      LGE using a hybrid PET/MRI system can help to predict functional recovery after 
      PCI in patients with CTO.
CI  - (c) 2020. American Society of Nuclear Cardiology.
FAU - Kiko, Takatoyo
AU  - Kiko T
AD  - Department of Cardiovascular Medicine, Fukushima Medical University, 1 
      Hikarigaoka, Fukushima, Japan. tkiko@fmu.ac.jp.
FAU - Yokokawa, Tetsuro
AU  - Yokokawa T
AD  - Department of Cardiovascular Medicine, Fukushima Medical University, 1 
      Hikarigaoka, Fukushima, Japan.
FAU - Misaka, Tomofumi
AU  - Misaka T
AD  - Department of Cardiovascular Medicine, Fukushima Medical University, 1 
      Hikarigaoka, Fukushima, Japan.
FAU - Masuda, Atsuro
AU  - Masuda A
AD  - Department of Diagnostic Radiology, Tohoku University Hospital, Sendai, Japan.
FAU - Yoshihisa, Akiomi
AU  - Yoshihisa A
AD  - Department of Cardiovascular Medicine, Fukushima Medical University, 1 
      Hikarigaoka, Fukushima, Japan.
FAU - Yamaki, Takayoshi
AU  - Yamaki T
AD  - Department of Cardiovascular Medicine, Fukushima Medical University, 1 
      Hikarigaoka, Fukushima, Japan.
FAU - Kunii, Hiroyuki
AU  - Kunii H
AD  - Department of Cardiovascular Medicine, Fukushima Medical University, 1 
      Hikarigaoka, Fukushima, Japan.
FAU - Nakazato, Kazuhiko
AU  - Nakazato K
AD  - Department of Cardiovascular Medicine, Fukushima Medical University, 1 
      Hikarigaoka, Fukushima, Japan.
FAU - Takeishi, Yasuchika
AU  - Takeishi Y
AD  - Department of Cardiovascular Medicine, Fukushima Medical University, 1 
      Hikarigaoka, Fukushima, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200130
PL  - United States
TA  - J Nucl Cardiol
JT  - Journal of nuclear cardiology : official publication of the American Society of 
      Nuclear Cardiology
JID - 9423534
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Aged
MH  - Chronic Disease
MH  - Coronary Occlusion/*diagnostic imaging/physiopathology/therapy
MH  - Female
MH  - Fluorodeoxyglucose F18/*pharmacokinetics
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - *Positron-Emission Tomography
MH  - Radiopharmaceuticals/*pharmacokinetics
MH  - Recovery of Function
MH  - Stroke Volume/physiology
MH  - Ventricular Function, Left/*physiology
OTO - NOTNLM
OT  - CAD
OT  - MRI
OT  - PET
OT  - hybrid imaging
EDAT- 2020/02/01 06:00
MHDA- 2022/03/23 06:00
CRDT- 2020/02/01 06:00
PHST- 2019/11/06 00:00 [received]
PHST- 2020/01/13 00:00 [accepted]
PHST- 2020/02/01 06:00 [pubmed]
PHST- 2022/03/23 06:00 [medline]
PHST- 2020/02/01 06:00 [entrez]
AID - S1071-3581(23)01589-1 [pii]
AID - 10.1007/s12350-020-02041-3 [doi]
PST - ppublish
SO  - J Nucl Cardiol. 2021 Oct;28(5):2335-2342. doi: 10.1007/s12350-020-02041-3. Epub 
      2020 Jan 30.